BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1449 related articles for article (PubMed ID: 23448451)

  • 1. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological complications of Anderson-Fabry disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Arnao V; Licata G; Pinto A
    Curr Pharm Des; 2013; 19(33):6014-30. PubMed ID: 23448452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
    Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: recognition and management of cutaneous manifestations.
    Möhrenschlager M; Braun-Falco M; Ring J; Abeck D
    Am J Clin Dermatol; 2003; 4(3):189-96. PubMed ID: 12627994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The heart in Fabry's disease.
    Sheppard MN
    Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal complications of Fabry disease in children.
    Najafian B; Mauer M; Hopkin RJ; Svarstad E
    Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies.
    Tuttolomondo A; Simonetta I; Riolo R; Todaro F; Di Chiara T; Miceli S; Pinto A
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Mainz Severity Score Index (MSSI): development and validation of a system for scoring the signs and symptoms of Fabry disease.
    Beck M
    Acta Paediatr Suppl; 2006 Apr; 95(451):43-6. PubMed ID: 16720464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
    Gupta S; Ries M; Kotsopoulos S; Schiffmann R
    Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease: cardiac manifestations and therapeutic options.
    Pierre-Louis B; Kumar A; Frishman WH
    Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: Review and experience during newborn screening.
    Hsu TR; Niu DM
    Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.
    Meehan SM; Junsanto T; Rydel JJ; Desnick RJ
    Am J Kidney Dis; 2004 Jan; 43(1):164-71. PubMed ID: 14712441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 73.